Prozac

Fluoxetine HCl

Symptomatic treatment of depression w/ or w/o anxiety. Obsessive compulsive disorder, pre-menstrual dysphoric disorder (PMDD).

Depression w/ or w/o anxiety & obsessive-compulsive disorder 20 mg daily, may be increased gradually up to max: 60 mg. PMDD 20 mg daily. Elderly Daily dose: Not to exceed 40 mg. Max: 60 mg daily.

May be taken with or without food.

Hypersensitivity. Concomitant use w/ irreversible & non-selective MAOIs, metoprolol.

Rash & allergic reactions. Suicide/suicidal thoughts, history of suicide-related events; congenital long QT syndrome, family history of QT prolongation, hypokalemia, hypomagnesemia, bradycardia, acute MI or uncompensated heart failure; serotonin-syndrome or NMS-like events; history of mania/hypomania; history of bleeding disorders; unstable seizure disorders/epilepsy, controlled epilepsy; patients receiving electoconvulsive therapy; akathisia/psychomotor restlessness; diabetes; raised IOP or at risk of narrow-angle glaucoma. Avoid abrupt w/drawal. Discontinue use in any patient entering manic phase. Concomitant use w/ medicinal products inducing QT prolongation &/or Torsade de pointes; oral anticoagulants, atypical antipsychotics, TCAs, aspirin, NSAIDs, drugs increasing risk of bleeding, tamoxifen. Hepatic & renal function. May affect ability to drive & use machines. Not be used during pregnancy & lactation. Suicidality in childn & adolescents. Elderly.

Insomnia; headache; diarrhoea, nausea; fatigue. Decreased appetite; anxiety, nervousness, restlessness, tension, decreased libido, sleep disorder, abnormal dreams; disturbance in attention, dizziness, dysgeusia, lethargy, somnolence, tremor; blurred vision; palpitations, ECG QT prolongation; flushing; yawning; vomiting, dyspepsia, dry mouth; rash, urticaria, pruritus, hyperhidrosis; arthralgia; frequent urination; gynaecological bleeding, erectile dysfunction, ejaculation disorder; feeling jittery, chills; decreased wt.

Risk of serotonin syndrome w/ irreversible, non-selective MAOIs, linezolid & methylene blue. Inhibited metabolism of metoprolol, mequitazine. Reduced efficacy of tamoxifen. Changes in blood levels w/ phenytoin. Prolonged QT interval w/ class IA & III antiarrythmics, antipsychotics, TCAs, sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, halofantrine, astemizole, mizolastine. Risk of increased bleeding w/ oral anticoagulant, aspirin & NSAIDs. Reduced antidepressant activity w/ cyproheptadine. Increased risk of hyponatremia w/ diuretics, desmopressin, carbamazepine, oxcarbazepine. Lowered seizure threshold w/ TCAs, other SSRIs, phenothiazines, butyrophenones, mefloquine, chloroquine, bupropion, tramadol. Concomitant use w/ drugs metabolized by CYP2D6 eg, fleicainide, propafenone, nebivolol, atomoxetine, carbamazepine; iproniazid, alcohol, lithium, tramadol, triptans, tryptophan, selegiline, St. John's wort, flecainide, propafenone, nebivolol, atomoxetine, risperidone.

Antidepressants

N06AB03 - fluoxetine ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.

B